Standout Papers

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular ... 2014 2026 2018 2022 323
  1. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice (2014)
    Bo-Wen Lin, Nobutaka Koibuchi et al. Cardiovascular Diabetology

Immediate Impact

6 from Science/Nature 65 standout
Sub-graph 1 of 24

Citing Papers

Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure
2025 Standout
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
2024 Standout
2 intermediate papers

Works of Hiroaki Kusaka being referenced

Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
2016
LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone
2015
and 1 more

Author Peers

Author Last Decade Papers Cites
Hiroaki Kusaka 398 62 400 350 25 1.2k
Weidong Chai 310 14 343 492 33 1.4k
Pawel Namsolleck 532 13 368 637 35 1.4k
Jey Sook Chae 275 19 353 252 45 1.3k
Giuliana Properzi 181 154 350 196 22 1.2k
Jaak Kals 591 55 163 302 73 1.5k
Susana Novella 280 11 289 571 57 1.7k
Ismail Patimah 200 33 159 324 18 1.6k
Meijun Li 319 23 698 388 34 1.5k
Aurélie Cotillard 451 5 160 537 20 1.5k
Carlos Fernández‐Fernández 156 90 333 617 27 1.7k

All Works

Loading papers...

Rankless by CCL
2026